Sepsis Diagnostics Market

Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

Report Code: MD 4575 Apr, 2024, by marketsandmarkets.com

The global size of sepsis diagnostics market in terms of revenue was estimated to be worth $634 million in 2024 and is poised to reach $890 million by 2029, growing at a CAGR of 7.0% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

During the forecast years, the growth of the market is attributed to the growing burden of infectious diseases, growing government initiatives for creating sepsis awareness, the increasing public-private funding for sepsis diagnostic research activities, and the rising number of sepsis incidences.

Global Sepsis Diagnostics Industry Trends

Sepsis Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Sepsis Diagnostics Market Opportunities

Sepsis Diagnostics Market Dynamics

Driver: Increasing hospital-acquired infection incidences

The main driving force for the growth of the sepsis diagnostics market is the rising incidence of Hospital-acquired infections (HAIs). Hospital-acquired infections (healthcare-associated infections) are nosocomially acquired infections that are not present or incubating at the time of admission to a hospital. Globally there is a rapid increase in HAIs, due to which in the coming years the demand for sepsis diagnostic products is also expected to rise. In the US, sepsis is the third most common cause of death in U.S. hospitals affecting 1.7 million people nationwide each year (Source: Centers for Disease Control and Prevention (CDC)).

Restraint: High costs of automated diagnostic devices

The material used in the development of diagnostic devices significantly contribute to the cost of the automated diagnostic devices. For instance, the price of the molecular diagnostic tests is USD 300–3,000 (and above), thus diagnostic devices are too expensive (with advanced materials) to be used on a regular basis (mainly in the developing markets). The price is very high compared to the cost of blood culture tests, priced as low as ~USD 28–35. Further, though in developed countries sepsis diagnosis is relatively common, automated diagnostic devices are still unaffordable in countries with a per capita government healthcare expenditure below USD 50. Government hospitals (especially in emerging nations) and academic research laboratories due to limited budgets, cannot afford such systems.

Opportunity: Rapid diagnostic/POC techniques development for early sepsis diagnosis

The product offering are being expanded by many sepsis diagnostic manufacturers in point of care (POC) technology for rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. Within three hours in septic shock, the risk of mortality increases by 35% with every one hour delay in antibiotic administration. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis. Becton Dickinson and Company (US) manufacture blood culturing instruments like BACTEC FX, BACTEC Plus and BacT/Alert which are automated microbial detection systems offering a rapid diagnosis of sepsis in the minimum turnaround time.

Challenge: Dearth of skilled healthcare professionals

The shortage of skilled professionals is a major concern worldwide. Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The lack of trained paramedics affects each phase of patient care— screening patients for the presence of sepsis and sepsis awareness. Only 50% of patients with severe sepsis transported by the EMS system have a paramedic.

Sepsis Diagnostics Market Ecosystem

Sepsis Diagnostics Market Ecosystem

By technology, the blood culture segment accounted for the largest share of sepsis diagnostics industry during the forecast period.

Based on the technology, the sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Molecular diagnostics is further sub-segmented into PCR, microarray, peptide nucleic acid fluorescent in situ hybridization and DNA sequencing. The blood culture segment accounts for the largest share of the sepsis diagnostics market. The extensive use of blood culture methods for the diagnosis of sepsis and the low cost of microbiology techniques contribute to the large share.

By product, the blood culture media segment of sepsis diagnostics industry is expected to grow at the highest rate during the forecast period.

Based on the product, the sepsis diagnostics is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2024, the blood culture media segment is expected accounted for the largest share of market during the forecast period. The increase in the availability of blood culture media and growing utilization of blood culture media by hospitals & pathology laboratories for the diagnosis of sepsis has led to the growth of the segment.

By pathogen type, the bacterial sepsis segment of sepsis diagnostics industry is expected to witness significant growth during the forecast period.

Based on the pathogen type, the sepsis diagnostics is segmented into bacterial sepsis, fungal sepsis, and other pathogen. The other pathogen segment of the sepsis diagnostics market includes viral sepsis and parasitic sepsis. The bacterial sepsis segment is expected to witness significant growth during the forecast period. the rising prevalence of HAIs and the increasing number of surgical procedures have led to the significant growth and dominance of the segment in the industry in the upcoming years.

North America is expected to be the largest market of sepsis diagnostics industry during the forecast period.

Sepsis Diagnostics Market by Region

The sepsis diagnostics market has been segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America, comprising the US and Canada, held the largest share of the global market in 2023. This region is witnessing growth due to rising number of surgical procedures, the presence of a highly developed healthcare system, technological advancements, increasing incidence of health-associated infections (HAIs) and high adoption of innovative sepsis diagnostic technologies among medical professionals.

On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. North America accounted for a share of 43.4% of the market, followed by Europe with a share of 30.7%.

To know about the assumptions considered for the study, download the pdf brochure

As of 2023, prominent players in the Sepsis diagnostics market are bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), QuidelOrtho Corporation (US), F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), among others.

Scope of the Sepsis Diagnostics Industry

Report Metric

Details

Market Revenue in 2024

$634 million

Projected Revenue by 2029

$890 million

Revenue Rate

Poised to grow at a CAGR of 7.0%

Market Driver

Increasing hospital-acquired infection incidences

Market Opportunity

Rapid diagnostic/POC techniques development for early sepsis diagnosis

This study categorizes the global sepsis diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Technology

  • Blood Culture
  • Immunoassays
  • Molecular Diagnostics
    • PCR
    • Peptide Nucleic Acid-Fluorescent In Situ Hybridization
    • Microarrays
    • DNA sequencing
    • Syndromic Panel-Based Testing
  • Flow Cytometry
  • Microfluidics
  • Biomarkers

By Product

  • Blood Culture Media
  • Assays & Reagents
  • Instruments
  • Software

By Method

  • Automated Diagnostics
  • Conventional Diagnostics

By Pathogen Type

  • Bacterial Sepsis
    • Gram-Negative Bacterial Sepsis
    • Gram-Positive Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogen

By Test Type

  • Laboratory Tests
  • Point-of-Care Tests

By End User

  • Hospitals and specialty clinics
  • Pathology & Reference Laboratories
  • Research Laboratories, Academic Institutes & CROs

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • RoE
  • Asia Pacific
    • China
    • Japan
    • Australia
    • South Korea
    • India
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLATAM
  • Middle East & Africa
    • GCC Countries
    • Rest of the Middle East & Africa

Recent Developments of the Sepsis Diagnostics Industry

  • In April 2023, BioMérieux launched BIOFIRE FIREWORKS, an integrated software solution for BIOFIRE Systems optimizing laboratory services and supporting data-driven decisions.
  • In May 2023, Sysmex Corporation launched clinical flow cytometry system Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • In June 2023, T2 Biosystems collaborated with Vanderbilt University Medical Center to implement and evaluate the T2Bacteria Panel for clinical use.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 OBJECTIVES OF THE STUDY
    1.2 SEPSIS DIAGNOSTICS MARKET - MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY USED FOR THE STUDY
    1.5 MAJOR MARKET STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA SOURCES
                    2.1.1.1 Indicative list of secondary sources
           2.1.2 PRIMARY DATA SOURCES
                    FIGURE 2 BREAKDOWN OF PRIMARIES: SEPSIS DIAGNOSTICS MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
          FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
                    2.2.1.1 Procedure-based market estimation
                                FIGURE 4 MARKET SIZE ESTIMATION: BASED ON PROCEDURE METHODOLOGY
                                FIGURE 5 MARKET SIZE ESTIMATION: BASED ON REVENUE MAPPING METHODOLOGY
           2.2.2 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 9 SEPSIS DIAGNOSTICS INDUSTRY, BY METHOD, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 SEPSIS DIAGNOSTICS INDUSTRY, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE SEPSIS DIAGNOSTICS INDUSTRY

4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
          FIGURE 14 THE RISING INCIDENCE OF SEPSIS AND THE RISING NUMBER OF HOSPITAL-ACQUIRED INFECTIONS ARE KEY FACTORS DRIVING THE MARKET GROWTH
    4.2 GLOBAL MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
          FIGURE 15 MOLECULAR DIAGNOSTICS TO REGISTER THE HIGHEST GROWTH IN THE MARKET DURING THE FORECAST PERIOD
    4.3 GLOBAL MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION)
          FIGURE 16 CONVENTIONAL DIAGNOSTICS IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY METHOD, DURING THE FORECAST PERIOD
    4.4 ASIA PACIFIC: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2021)
          FIGURE 17 BLOOD CULTURE MEDIA SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET FOR APAC
    4.5 GEOGRAPHIC SNAPSHOT OF THE GLOBAL MARKET
          FIGURE 18 APAC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2021–2026)

5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High incidence of sepsis
                    5.2.1.2 Rising incidence of hospital-acquired infections
                    5.2.1.3 Growing funding for sepsis-related research
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of automated diagnostic devices
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
                    5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
                    5.2.3.3 Growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis
                    5.2.4.2 Shortage of skilled healthcare professionals
    5.3 REGULATORY LANDSCAPE
           5.3.1 NORTH AMERICA
                    5.3.1.1 US
                    5.3.1.2 Canada
           5.3.2 EUROPE
           5.3.3 ASIA PACIFIC
                    5.3.3.1 China
                    5.3.3.2 Japan
                    5.3.3.3 India
           5.3.4 LATIN AMERICA
    5.4 PATENT ANALYSIS
          FIGURE 20 TOP 10 PATENT APPLICANTS FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021)
          FIGURE 21 NUMBER OF GRANTED PATENT AND PATENT APPLICATIONS FILED BY APPLICATIONS (JANUARY 2011 TO DECEMBER 2021)
          FIGURE 22 PATENT DOCUMENTS FOR SEPSIS DIAGNOSTICS, BY LEGAL STATUS (JANUARY 2011 TO DECEMBER 2021)
          FIGURE 23 REGIONAL ANALYSIS OF PATENTS GRANTED FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021)
    5.5 COVID-19 IMPACT ON THE GLOBAL MARKET
    5.6 VALUE CHAIN ANALYSIS
          FIGURE 24 VALUE CHAIN OF THE GLOBAL MARKET
    5.7 PRICING TREND ANALYSIS
          TABLE 1 AVERAGE PRICE OF SEPSIS DIAGNOSTICS BLOOD CULTURE MEDIA, ASSAYS & REAGENT KITS AND EQUIPMENT, BY COUNTRY, 2020 (USD)
    5.8 REIMBURSEMENT SCENARIO
          TABLE 2 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
    5.9 PORTER’S FIVE FORCES ANALYSIS
          TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
                    FIGURE 25 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
                    FIGURE 26 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF SUPPLIERS
                    FIGURE 27 BARGAINING POWER OF SUPPLIERS
           5.9.4 BARGAINING POWER OF BUYERS
                    FIGURE 28 BARGAINING POWER OF BUYERS
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
                    FIGURE 29 INTENSITY OF COMPETITIVE RIVALRY
    5.10 ECOSYSTEM COVERAGE

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 71)
    6.1 INTRODUCTION
           TABLE 4 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
           6.2.1 BLOOD CULTURE IS THE MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
                    TABLE 5 BLOOD CULTURE MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 6 BLOOD CULTURE MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 7 BLOOD CULTURE MARKET, BY METHOD, 2019–2026 (USD MILLION)
                    TABLE 8 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                    TABLE 9 BLOOD CULTURE MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 10 BLOOD CULTURE MARKET, BY END USER, 2019–2026(USD MILLION)
    6.3 IMMUNOASSAYS
           6.3.1 PRODUCT DEVELOPMENT BY MAJOR PLAYERS HAS ENSURED THE DEMAND FOR IMMUNOASSAYS
                    TABLE 11 IMMUNOASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 12 IMMUNOASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 13 IMMUNOASSAYS MARKET, BY METHOD, 2019–2026 (USD MILLION)
                    TABLE 14 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                    TABLE 15 IMMUNOASSAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 16 IMMUNOASSAYS DIAGNOSTICS MARKET, BY END USER,  2019–2026(USD MILLION)
    6.4 MOLECULAR DIAGNOSTICS
          TABLE 17 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026(USD MILLION)
          TABLE 18 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
          TABLE 19 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
          TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
          TABLE 21 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
          TABLE 22 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
          TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION)
           6.4.1 POLYMERASE CHAIN REACTION (PCR)
                    6.4.1.1 Quick turnaround time, coupled with technological advancements to increase the adoption of PCR for sepsis diagnosis
                                TABLE 24 PCR MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 25 PCR MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                TABLE 26 PCR MARKET, BY METHOD, 2019–2026 (USD MILLION)
                                TABLE 27 PCR MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                                TABLE 28 PCR MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                                TABLE 29 PCR MARKET, BY END USER, 2019–2026(USD MILLION)
           6.4.2 DNA MICROARRAYS
                    6.4.2.1 Simultaneous analysis capabilities & accuracy have driven the use of microarrays
                                TABLE 30 DNA MICROARRAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 31 DNA MICROARRAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                TABLE 32 DNA MICROARRAYS MARKET, BY METHOD, 2019–2026 (USD MILLION)
                                TABLE 33 DNA MICROARRAYS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                                TABLE 34 DNA MICROARRAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                                TABLE 35 DNA MICROARRAYS MARKET, BY END USER, 2019–2026(USD MILLION)
           6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION (PNA-FISH)
                    6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of bloodstream infections (BSIs)
                                TABLE 36 PNA-FISH MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 37 PNA-FISH MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                TABLE 38 PNA-FISH MARKET, BY METHOD, 2019–2026 (USD MILLION)
                                TABLE 39 PNA-FISH MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                                TABLE 40 PNA-FISH MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                                TABLE 41 PNA-FISH MARKET, BY END USER, 2019–2026(USD MILLION)
           6.4.4 DNA SEQUENCING
                    6.4.4.1 DNA Sequencing shortens the time for sepsis diagnosis, and NGS has applications in COVID-19 diagnosis
                                TABLE 42 DNA SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 43 DNA SEQUENCING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                TABLE 44 DNA SEQUENCING MARKET, BY METHOD, 2019–2026 (USD MILLION)
                                TABLE 45 DNA SEQUENCING MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                                TABLE 46 DNA SEQUENCING MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                                TABLE 47 DNA SEQUENCING MARKET, BY END USER, 2019–2026(USD MILLION)
           6.4.5 SYNDROMIC PANEL-BASED TESTING
                    6.4.5.1 High costs and accuracy errors limit the adoption of syndromic-panel-based tests
                                TABLE 48 SYNDROMIC PANEL-BASED TESTING MARKET, BY REGION, 2019–2026 (USD MILLION)
                                TABLE 49 SYNDROMIC PANEL-BASED TESTING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                TABLE 50 SYNDROMIC PANEL-BASED TESTING MARKET, BY METHOD, 2019–2026 (USD MILLION)
                                TABLE 51 SYNDROMIC PANEL-BASED TESTING MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                                TABLE 52 SYNDROMIC PANEL-BASED TESTING MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                                TABLE 53 SYNDROMIC PANEL-BASED TESTING MARKET, BY END USER, 2019–2026(USD MILLION)
    6.5 FLOW CYTOMETRY
           6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN FLOW CYTOMETRY
                    TABLE 54 FLOW CYTOMETRY MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 55 FLOW CYTOMETRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 56 FLOW CYTOMETRY MARKET, BY METHOD, 2019–2026 (USD MILLION)
                    TABLE 57 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                    TABLE 58 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 59 FLOW CYTOMETRY MARKET, BY END USER, 2019–2026(USD MILLION)
    6.6 MICROFLUIDICS
           6.6.1 RISING ADOPTION OF ADVANCED & RAPID TESTING TO DRIVE THE GROWTH OF THE MICROFLUIDICS SEGMENT
                    TABLE 60 MICROFLUIDICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 61 MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 62 MICROFLUIDICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
                    TABLE 63 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                    TABLE 64 MICROFLUIDICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 65 MICROFLUIDICS MARKET, BY END USER, 2019–2026(USD MILLION)
    6.7 BIOMARKERS
           6.7.1 RESEARCH & DEVELOPMENT FOR THE DISCOVERY OF NOVEL BIOMARKERS TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 66 BIOMARKERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 67 BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 68 BIOMARKERS MARKET, BY METHOD, 2019–2026 (USD MILLION)
                    TABLE 69 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                    TABLE 70 BIOMARKERS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                    TABLE 71 BIOMARKERS MARKET, BY END USER, 2019–2026(USD MILLION)

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 100)
    7.1 INTRODUCTION
           TABLE 72 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
    7.2 BLOOD CULTURE MEDIA
           7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE THE GROWTH OF BLOOD CULTURE MEDIA IN SEPSIS DIAGNOSIS
                     FIGURE 30 INCIDENCE OF BLOODSTREAM INFECTIONS BY AGE AND SEX, WESTERN INTERIOR OF BRITISH COLUMBIA AND CANADA, 2010–2019
                     TABLE 73 BLOOD CULTURE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 ASSAYS & REAGENT KITS
           7.3.1 ASSAYS BETTER ENABLE THE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
                    TABLE 74 ASSAYS & REAGENT KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.4 INSTRUMENTS
           7.4.1 TRADITIONAL DIAGNOSTIC INSTRUMENTS ARE GRADUALLY BEING REPLACED BY AUTOMATED INSTRUMENTS
                    TABLE 75 INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.5 SOFTWARE
           7.5.1 RISING USE OF AUTOMATED INSTRUMENTS TO ENSURE THE GROWING DEMAND FOR SOFTWARE
                    TABLE 76 SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION)

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD (Page No. - 106)
    8.1 INTRODUCTION
          TABLE 77 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY, BY METHOD, 2019–2026 (USD MILLION)
           8.1.1 CONVENTIONAL DIAGNOSTICS
                    8.1.1.1 Higher adoption of conventional diagnostics owing to blood culture testing to drive the growth of this segment
                                TABLE 78 CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           8.1.2 AUTOMATED DIAGNOSTICS
                    8.1.2.1 Accuracy & quick turnaround times to drive the adoption of automated diagnostics among medical professionals
                                TABLE 79 AUTOMATED DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE (Page No. - 110)
    9.1 INTRODUCTION
          TABLE 80 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
    9.2 BACTERIAL SEPSIS
          TABLE 81 BACTERIAL SEPSIS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
                    9.2.1.1 Increased proportion of sepsis infection caused by gram-negative bacteria
                                TABLE 82 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULT SEPSIS
                                TABLE 83 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
           9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
                    9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years
                                TABLE 84 GRAM-POSITIVE BACTERIAL CAUSES IN ADULT SEPSIS
                                TABLE 85 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.3 FUNGAL SEPSIS
           9.3.1 THE RISING INCIDENCE OF FUNGAL HAIS HAS INCREASED THE RISK OF SEPSIS DEVELOPMENT
                    TABLE 86 FUNGAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.4 VIRAL SEPSIS
           9.4.1 VIRAL PATHOGEN A NEW CAUSATIVE AGENT OF SEPSIS
                    TABLE 87 VIRAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.5 OTHER PATHOGENS
          TABLE 88 OTHER PATHOGENS MARKET, BY REGION, 2019–2026 (USD MILLION)

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 117)
     10.1 INTRODUCTION
             TABLE 89 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2019–2026 (USD MILLION)
     10.2 LABORATORY TESTS
             10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING
                       TABLE 90 LABORATORY TEST MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2019–2026(USD MILLION)
     10.3 POINT-OF-CARE TESTS
             10.3.1 RAPID POC TESTING DRIVES THE GROWTH OF THIS SEGMENT
                       TABLE 91 POC TESTS MARKET FOR SEPSIS DIAGNOSTICS, NY REGION, 2019–2026(USD MILLION)

11 SEPSIS DIAGNOSTICS MARKET, BY END USER (Page No. - 121)
     11.1 INTRODUCTION
             TABLE 92 SEPSIS DIAGNOSTICS INDUSTRY, BY END USER, 2019–2026(USD MILLION)
     11.2 HOSPITALS AND SPECIALTY CLINICS
             11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO BOOST SEGMENT GROWTH
                       TABLE 93 MARKET FOR HOSPITALS AND SPECILAITY CLINICS, BY REGION, 2019–2026 (USD MILLION)
     11.3 PATHOLOGY & REFERENCE LABORATORIES
             11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
                       TABLE 94 MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
     11.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
             11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION DRIVES THE GROWTH OF THIS SEGMENT
                       TABLE 95 MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)

12 SEPSIS DIAGNOSTICS MARKET, BY REGION (Page No. - 126)
     12.1 INTRODUCTION
     12.2 NORTH AMERICA
             FIGURE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
             TABLE 96 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 97 NORTH AMERICA: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 98 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 99 NORTH AMERICA: MARKET, BY METHOD,  2019–2026 (USD MILLION)
             TABLE 100 NORTH AMERICA: SEPSIS DIAGNOSTICS INDUSTRY, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
             TABLE 101 NORTH AMERICA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
             TABLE 102 NORTH AMERICA: MARKET, BY END USER, 2019–2026(USD MILLION)
             12.2.1 US
                        12.2.1.1 Rising incidence of HIAS in us to accelerate the demand for sepsis diagnosis
                                      TABLE 103 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,  2019–2026 (USD MILLION)
                                      TABLE 104 US: MARKET FOR MOLECULAR DIAGNOSTICS,  BY TYPE, 2019–2026 (USD MILLION)
             12.2.2 CANADA
                        12.2.2.1 The growing availability of sepsis diagnostic products is expected to drive market growth in Canada
                                      TABLE 105 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 106 CANADA: MARKET FOR MOLECULAR DIAGNOSTICS,  BY TYPE, 2019–2026 (USD MILLION)
     12.3 EUROPE
             TABLE 107 EUROPE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 108 EUROPE: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 109 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
             TABLE 111 EUROPE: MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
             TABLE 112 EUROPE: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
             TABLE 113 EUROPE: SEPSIS DIAGNOSTICS INDUSTRY, BY END USER,  2019–2026(USD MILLION)
             12.3.1 GERMANY
                        12.3.1.1 Growing awareness and the adoption of technologically advanced diagnostics products in Germany to drive the market growth
                                     TABLE 114 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 115 GERMANY: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.3.2 UK
                        12.3.2.1 Government support and rising awareness for the early diagnosis of sepsis are the key factors driving market growth in the UK
                                     TABLE 116 UK: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 117 UK: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.3.3 FRANCE
                        12.3.3.1 The high incidence of sepsis in France has supported the demand for sepsis diagnostic products
                                     TABLE 118 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,  2019–2026 (USD MILLION)
                                     TABLE 119 FRANCE: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.3.4 ITALY
                        12.3.4.1 Limited growth in the healthcare sector to restrain the market growth for sepsis diagnostics in Italy
                                     TABLE 120 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 121 ITALY: MARKET FOR MOLECULAR DIAGNOSTICS,  BY TYPE, 2019–2026 (USD MILLION)
             12.3.5 SPAIN
                        12.3.5.1 Rising awareness for the early diagnosis of sepsis to drive the market growth in Spain
                                     TABLE 122 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,  2019–2026 (USD MILLION)
                                     TABLE 123 SPAIN: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.3.6 REST OF EUROPE
                       TABLE 124 REST OF EUROPE: SEPSIS DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 125 REST OF EUROPE: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
     12.4 ASIA PACIFIC
             TABLE 126 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 127 ASIA PACIFIC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 128 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 129 ASIA PACIFIC: MARKET, BY METHOD, 2019–2026 (USD MILLION)
             TABLE 130 ASIA PACIFIC: MARKET, BY PATHOGEN TYPE,  2019–2026 (USD MILLION)
             TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2019–2026 (USD MILLION)
             TABLE 132 ASIA PACIFIC: MARKET, BY END USER, 2019–2026(USD MILLION)
             12.4.1 JAPAN
                        12.4.1.1 Rising incidence of pneumonia and infectious diseases to support the market growth in Japan
                                     TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 134 JAPAN: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.4.2 CHINA
                        12.4.2.1 Healthcare infrastructure improvements to support the market growth for sepsis diagnostics in China
                                     TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 136 CHINA: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.4.3 INDIA
                        12.4.3.1 Increasing patient population and the rising number of surgical procedures to drive the market growth in India
                                     TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 138 INDIA: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.4.4 AUSTRALIA
                        12.4.4.1 The increasing number of sepsis treatment procedures indicates growth potential for the market in Australia
                                     TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 140 AUSTRALIA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.4.5 SOUTH KOREA
                        12.4.5.1 Rising healthcare spending to support the market  growth in South Korea
                                     TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,  2019–2026 (USD MILLION)
                                     TABLE 142 SOUTH KOREA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.4.6 THE REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 143 ROAPAC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 144 ROAPAC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
     12.5 LATIN AMERICA
             TABLE 145 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 146 LATIN AMERICA: MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 147 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,  2019–2026 (USD MILLION)
             TABLE 148 LATIN AMERICA: MARKET, BY METHOD, 2019–2026 (USD MILLION)
             TABLE 149 LATIN AMERICA: MARKET, BY PATHOGEN TYPE,  2019–2026 (USD MILLION)
             TABLE 150 LATIN AMERICA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
             TABLE 151 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION)
             12.5.1 BRAZIL
                        12.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020 owing to the ongoing investments by manufacturers in the country
                                     TABLE 152 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,  2019–2026 (USD MILLION)
                                     TABLE 153 BRAZIL: MARKET FOR MOLECULAR DIAGNOSTICS,  BY TYPE, 2019–2026 (USD MILLION)
             12.5.2 MEXICO
                        12.5.2.1 Rising medical tourism to support the market growth in Mexico
                                     TABLE 154 MEXICO: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 155 MEXICO: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
             12.5.3 THE REST OF LATIN AMERICA (ROLATAM)
                        TABLE 156 ROLATAM: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 157 ROLATAM: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
     12.6 MIDDLE EAST & AFRICA
             12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS DRIVES SEPSIS OCCURRENCE IN THE MEA REGION
                        TABLE 158 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 159 MIDDLE EAST & AFRICA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY METHOD,  2019–2026 (USD MILLION)
                        TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)
                        TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
                        TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS INDUSTRY, BY END USER, 2019–2026(USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 168)
     13.1 OVERVIEW
     13.2 KEY PLAYER STRATEGIES
     13.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     13.4 MARKET SHARE ANALYSIS (2020)
             TABLE 165 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     13.5 COMPETITIVE LEADERSHIP MAPPING
             13.5.1 STARS
             13.5.2 PERVASIVE PLAYERS
             13.5.3 EMERGING LEADERS
             13.5.4 PARTICIPANTS
                        FIGURE 33 GLOBAL SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     13.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
                        FIGURE 34 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
     13.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL MARKET
             TABLE 166 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL MARKET
             TABLE 167 PRODUCT FOOTPRINT OF COMPANIES
             TABLE 168 REGIONAL FOOTPRINT OF COMPANIES
     13.8 COMPETITIVE SCENARIO
             13.8.1 GLOBAL SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS
                        TABLE 169 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS, JANUARY 2018–DECEMBER 2021
             13.8.2 GLOBAL SEPSIS DIAGNOSTICS INDUSTRY: DEALS
                        TABLE 170 KEY DEALS, JANUARY 2018–DECEMBER 2021
             13.8.3 SEPSIS DIAGNOSTICS INDUSTRY: OTHER DEVELOPMENTS
                        TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2018–DECEMBER 2021

14 COMPANY PROFILES (Page No. - 181)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     14.1 BIOMÉRIEUX
             TABLE 172 BIOMÉRIEUX.: BUSINESS OVERVIEW
             FIGURE 35 BIOMÉRIEUX: COMPANY SNAPSHOT (2020)
             TABLE 173 BIOMÉRIEUX.: PRODUCT OFFERINGS
     14.2 BECTON, DICKINSON, AND COMPANY
             TABLE 174 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW
             FIGURE 36 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2020)
             TABLE 175 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
     14.3 DANAHER CORPORATION
             TABLE 176 DANAHER CORPORATION: BUSINESS OVERVIEW
             FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             TABLE 177 DANAHER CORPORATION: PRODUCT OFFERINGS
     14.4 T2 BIOSYSTEMS
             TABLE 178 T2 BIOSYSTEMS: BUSINESS OVERVIEW
             FIGURE 38 T2 BIOSYSTEMS: COMPANY SNAPSHOT (2020)
             TABLE 179 T2 BIOSYSTEMS: PRODUCT OFFERINGS
     14.5 LUMINEX
             TABLE 180 LUMINEX: BUSINESS OVERVIEW
             FIGURE 39 LUMINEX: COMPANY SNAPSHOT (2020)
             TABLE 181 LUMINEX: PRODUCT OFFERINGS
     14.6 F. HOFFMANN-LA ROCHE AG
             TABLE 182 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
             FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             TABLE 183 F. HOFFMANN-LA ROCHE AG: PRODUCT OFFERINGS
     14.7 THERMO FISHER SCIENTIFIC
             TABLE 184 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
             FIGURE 41 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
             TABLE 185 THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS
     14.8 BRUKER CORPORATION
             TABLE 186 BRUKER CORPORATION: BUSINESS OVERVIEW
             FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2020)
             TABLE 187 BRUKER CORPORATION: PRODUCT OFFERINGS
     14.9 ABBOTT LABORATORIES
             TABLE 188 ABBOTT LABORATORIES: BUSINESS OVERVIEW
             FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             TABLE 189 ABBOTT LABORATORIES: PRODUCT OFFERINGS
     14.10 QUIDEL CORPORATION
              TABLE 190 QUIDEL CORPORATION: BUSINESS OVERVIEW
              FIGURE 44 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
              TABLE 191 QUIDEL CORPORATION: PRODUCT OFFERINGS
     14.11 SIEMENS HEALTHINEERS
              TABLE 192 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
              FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
              TABLE 193 SIEMENS HEALTHINEERS: PRODUCT OFFERINGS
     14.12 EKF DIAGNOSTICS
              TABLE 194 EKF DIAGNOSTICS: BUSINESS OVERVIEW
              FIGURE 46 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020)
              TABLE 195 EKF DIAGNOSTICS: PRODUCT OFFERINGS
     14.13 SYSMEX CORPORATION
              TABLE 196 SYSMEX CORPORATION: BUSINESS OVERVIEW
              FIGURE 47 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
              TABLE 197 SYSMEX CORPORATION: PRODUCT OFFERINGS
     14.14 SEEGENE, INC.
              TABLE 198 SEEGENE, INC.: BUSINESS OVERVIEW
              TABLE 199 SEEGENE, INC: PRODUCT OFFERINGS
     14.15 RESPONSE BIOMEDICAL CORP.
              TABLE 200 RESPONSE BIOMEDICAL CORP.: BUSINESS OVERVIEW
              TABLE 201 RESPONSE BIOMEDICAL CORP.: PRODUCT OFFERINGS
     14.16 OTHER COMPANIES
             14.16.1 ALIFAX S.R.L.
             14.16.2 BODITECH MED INC.
             14.16.3 ADVANDX
             14.16.4 IMMUNEXPRESS INC.
             14.16.5 AXIS-SHIELD DIAGNOSTICS

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 228)
     15.1 DISCUSSION GUIDE
     15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     15.3 AVAILABLE CUSTOMIZATIONS
     15.4 RELATED REPORTS
     15.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the sepsis diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the sepsis diagnostics market. The primary sources from the demand side include OEMs, private and contract testing organizations and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Sepsis Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation Methodology

In this report, the global sepsis diagnostics market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the sepsis diagnostics products business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Approach 1: Procedure-based estimation approach

To calculate the global market value, installation/volume consumption of sepsis diagnostic products were calculated. This process involved the following steps:

  • Finding the total number of hospitalization at the regional and/or country-level
  • The average number of sepsis cases at the regional and/or country level
  • The average number of sepsis diagnostics tests performed per patient at the regional and/or country-level
  • The average selling price of each product type for a given year was triangulated to arrive at the market value data at the regional and/or country-level

Sepsis Diagnostics Market Size Estimation

Approach 2: End user-based market estimation

During preliminary secondary research, the total sales revenue of sepsis diagnostics was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

  • Generating a list of major customer facilities across each region and country
  • Identifying the average number of sepsis diagnostics product supplies used by major customer facilities across each product type at the regional/country level, annually
  • Identifying the percentage contribution of major customer facilities to the overall sepsis diagnostics expenditure and usage at the regional/country level, annually
  • Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually

Sepsis Diagnostics Market Size Estimation

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global sepsis diagnostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the sepsis diagnostics market was validated using both top-down and bottom-up approaches.

Market Definition

Sepsis is a life-threatening condition caused by pathogen infection. It develops when chemicals released into the bloodstream to fight the infection trigger inflammatory responses throughout the body. This is a three-stage syndrome—from sepsis to severe sepsis and septic shock. Septic shock is the last stage that results in extremely low blood pressure and a lack of response to normal fluid replacement. Inflammation leads to multi-organ failure; progress to septic shock could lead to death.

Key Market Stakeholders

  • Sepsis diagnostics reagents, instruments, blood culture media manufacturers
  • Research & academic laboratories
  • Healthcare service providers (including hospitals, reference labs, diagnostic centers, and specialty clinics)
  • Market research and consulting firms
  • Medical device suppliers, distributors, channel partners, and third-party suppliers
  • Business research and consulting service providers
  • Venture capitalists and other government funding organizations

Objectives of the Study

  • To define, describe, and forecast the sepsis diagnostics market on the basis of on technology, product, method, pathogen type, test type, end user and region.
  • To provide detailed information regarding the major factors influencing the growth potential of the global sepsis diagnostics market (drivers, restraints, opportunities, challenges, and trends).
  • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global sepsis diagnostics market.
  • To analyze key growth opportunities in the global sepsis diagnostics market for key stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa (GCC Countries and Rest of MEA).
  • To profile the key players in the global sepsis diagnostics market and comprehensively analyze their market shares and core competencies.
  • To track and analyze the competitive developments undertaken in the global sepsis diagnostics market, such as agreements, expansions, and & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global sepsis diagnostics market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis

  • Further breakdown of the Rest of Europe's sepsis diagnostics market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of Asia Pacific sepsis diagnostics market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Rest of the Latin America sepsis diagnostics market into Argentina, Chile, Peru, and Colombia, among other
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4575
Published ON
Apr, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback